Varied presentation of sinonasal phosphaturic mesenchymal tumour: report of a case series with follow-up

  • Regi KurienEmail author
  • Vedantam Rupa
  • Meera Thomas



Phosphaturic mesenchymal tumour (PMT) of the paranasal sinuses is a rare tumour that is associated with oncogenous osteomalacia causing predominant musculoskeletal symptoms. We present a series of eight patients diagnosed to have PMT of the paranasal sinuses with varied presentation and highlight the appropriate evaluation required to arrive at the diagnosis.


Retrospective review of eight patients diagnosed to have PMT-causing tumour-induced osteomalacia with follow-up data.


Eight patients, 4 males and 4 females, aged 36–67 years (mean = 44 years) presented with vague musculoskeletal symptoms (6 patients) or epistaxis (3 patients). Six patients were found to have hypophosphatemia, phosphaturia and raised FGF-23 levels preoperatively. All eight patients were found to have a tumour in the nose and/ paranasal sinuses with one patient having intracranial extension. All patients were treated with endoscopic excision of these tumours which resulted in resolution of symptoms and normalisation of biochemical abnormalities. In addition, one patient required a craniofacial resection. Histopathological features were consistent with PMT mixed connective tissue variant. Two atypical patients were seen. The longest follow-up was for 5 years and there was no evidence of recurrence during the follow-up period in any patient.


Diagnosis of PMT of the paranasal sinuses causing oncogenous osteomalacia requires a high index of suspicion when there are no ENT symptoms. Appropriate biochemical tests and histopathology lead to the correct diagnosis. Total endoscopic surgical excision leads to a good outcome.


Oncogenic osteomalacia Paranasal sinus Hypophosphatemia Hemangiopericytoma 




Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Institutional review board approval was obtained prior to the commencement of the retrospective study (IRB No:11,448).

Informed consent

Informed consent was obtained from all the participants in the study.


  1. 1.
    Weidner N, Santa Cruz D (1987) Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 59:1442–1454CrossRefGoogle Scholar
  2. 2.
    Folpe AL, Fanburg-Smith JC, Billings SD et al (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1–30CrossRefGoogle Scholar
  3. 3.
    Deep NL, Cain RB, McCullough AE et al (2014) Sinonasal phosphaturic mesenchymal tumor: Case report and systematic review. Allergy Rhinol Provid RI 5:162–167. CrossRefGoogle Scholar
  4. 4.
    Weidner N, Bar RS, Weiss D, Strottmann MP (1985) Neoplastic pathology of oncogenic osteomalacia/rickets. Cancer 55:1691–1705CrossRefGoogle Scholar
  5. 5.
    McCANCE RA (1947) Osteomalacia with Looser’s nodes (Milkman’s syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med 16:33–46Google Scholar
  6. 6.
    Kane SV, Kakkar A, Oza N et al (2017) Phosphaturic mesenchymal tumor of the nasal cavity and paranasal sinuses: a clinical curiosity presenting a diagnostic challenge. Auris Nasus Larynx. Google Scholar
  7. 7.
    Jan de Beur SM (2005) Tumor-induced osteomalacia. JAMA 294:1260–1267. CrossRefGoogle Scholar
  8. 8.
    Halperin F, Anderson RJ, Mulder JE (2007) Tumor-induced osteomalacia: the importance of measuring serum phosphorus levels. Nat Clin Pract Endocrinol Metab 3:721–725. CrossRefGoogle Scholar
  9. 9.
    Drezner MK (2001) Tumor-induced osteomalacia. Rev Endocr Metab Disord 2:175–186CrossRefGoogle Scholar
  10. 10.
    Shimada T, Hasegawa H, Yamazaki Y et al (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res Off J Am Soc Bone Miner Res 19:429–435. CrossRefGoogle Scholar
  11. 11.
    Komínek P, Stárek I, Geierová M et al (2011) Phosphaturic mesenchymal tumour of the sinonasal area: case report and review of the literature. Head Neck Oncol 3:16. CrossRefGoogle Scholar
  12. 12.
    Sandhu FA, Martuza RL (2000) Craniofacial hemangiopericytoma associated with oncogenic osteomalacia: case report. J Neurooncol 46:241–247CrossRefGoogle Scholar
  13. 13.
    Weidner N (1991) Review and update: oncogenic osteomalacia-rickets. Ultrastruct Pathol 15:317–333CrossRefGoogle Scholar
  14. 14.
    Leaf DE, Pereira RC, Bazari H, Jüppner H (2013) Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. J Clin Endocrinol Metab 98:887–891. CrossRefGoogle Scholar
  15. 15.
    Chong WH, Molinolo AA, Chen CC, Collins MT (2011) Tumor-induced osteomalacia. Endocr Relat Cancer 18:R53–R77. CrossRefGoogle Scholar
  16. 16.
    Clunie GP, Fox PE, Stamp TC (2000) Four cases of acquired hypophosphataemic (‘oncogenic’) osteomalacia. Problems of diagnosis, treatment and long-term management. Rheumatol Oxf Engl 39:1415–1421CrossRefGoogle Scholar
  17. 17.
    Ogose A, Hotta T, Emura I et al (2001) Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiol 30:99–103CrossRefGoogle Scholar
  18. 18.
    Harvey JN, Gray C, Belchetz PE (1992) Oncogenous osteomalacia and malignancy. Clin Endocrinol (Oxf) 37:379–382CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of ENTChristian Medical College and HospitalVelloreIndia
  2. 2.Department of PathologyChristian Medical College and HospitalVelloreIndia

Personalised recommendations